Michael Raab - 27 Jan 2026 Form 4 Insider Report for Tempest Therapeutics, Inc. (TPST)

Reporting relationship: Director
Issuer ticker: TPST
Reported as of: 27 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Jan 2026, 16:30:08 UTC
Prior SEC filing: 26 Jan 2026
Next SEC filing: 23 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Nicholas Maestas, Attorney-in-Fact

Key filing fact

Michael Raab filed Form 4 for Tempest Therapeutics, Inc. (TPST) on 28 Jan 2026.

Key facts

This page summarizes Michael Raab's Form 4 filing for Tempest Therapeutics, Inc. (TPST).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 28 Jan 2026, 16:30.

Change

Previous filing in this sequence was filed on 26 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001321402 Primary reporting owner

RAAB MICHAEL

Relationship: Director
Address: C/O TEMPEST THERAPEUTICS, INC., 2000 SIERRA POINT PARKWAY, SUITE 400, BRISBANE
Signature: /s/ Nicholas Maestas, Attorney-in-Fact
Signature date: 28 Jan 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TPST transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +1,230
Change %
Price: $0.000000
Shares after: 1,230
Date: 27 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,230
Exercise price: $2.94
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.